DA
YARW

DSC Advisors’s Yarrow Bioscience YARW Stock Holding History

DSC Advisors’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.31M Hold
13,929
– – 11.93% 3
2024
Q2 		$1.37M Hold
13,929
– – 4.58% 5
2024
Q1 		$2.14M Hold
13,929
– – 3.42% 7
2023
Q4 		$1.62M Buy
13,929
+11,629
+506% +$1.81M 2.68% 7
2023
Q3 		$460K Hold
2,300
– – 0.59% 15
2023
Q2 		$467K Hold
2,300
– – 0.7% 11
2023
Q1 		$354K Buy
2,300
+556
+32% +$99.8K 0.31% 12
2022
Q4 		$236K Sell
1,744
-1,223
-41% -$244K 0.54% 12
2022
Q3 		$596K Hold
2,967
– – 0.61% 28
2022
Q2 		$1.04M Hold
2,967
– – 1.04% 17
2022
Q1 		$1.74M Buy
2,967
+133
+5% +$79K 0.6% 17
2021
Q4 		$2.6M Buy
2,834
+1,612
+132% +$1.73M 2.01% 10
2021
Q3 		$1.53M Hold
1,222
– – 1.55% 14
2021
Q2 		$3.86M Buy
1,222
+69
+6% +$273K 2.79% 12
2021
Q1 		$7.11M Hold
1,153
– – 4.4% 7
2020
Q4 		$6.56M Hold
1,153
– – 5.42% 7
2020
Q3 		$6.89M Sell
1,153
-58
-5% -$338K 4.61% 7
2020
Q2 		$7.54M Buy
1,211
+634
+110% +$4.29M 8.27% 6
2020
Q1 		$5.56M Buy
+577
New +$9.05M 5.43% 8

Other funds holding YARW

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Exome Asset Management New York $162M AUM 259.04% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

DSC Advisors's YARW Position: Q3 2024 in Review

DSC Advisors held its Yarrow Bioscience (YARW) position steady in Q3 2024 at 13,929 shares worth $1.31M. The position accounts for 11.93% of the portfolio, ranked #3.

DSC Advisors first reported a position in YARW in Q1 2020 and has held it in 19 quarters since. The position peaked at $7.54M in Q2 2020. 32 funds tracked by Wall St. Rank hold YARW as of Q3 2024.

  • DSC Advisors held 13,929 shares of Yarrow Bioscience worth $1.31M as of Q3 2024.
  • DSC Advisors left its Yarrow Bioscience share count unchanged in Q3 2024.
  • Yarrow Bioscience made up 11.93% of DSC Advisors's portfolio in Q3 2024, its #3 holding.
  • DSC Advisors first reported a position in Yarrow Bioscience in Q1 2020 and has held it in 19 quarters since.
  • DSC Advisors's Yarrow Bioscience position peaked at $7.54M in Q2 2020.
  • 32 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q3 2024.

Based on DSC Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.